HCW Biologics Restates Q1 EPS Down 37% on Accounting Error
HCWB has more than doubled off its 52-week low of $1.5.
Summary
HCW Biologics announced it will restate Q1 2026 financials after discovering an EPS overstatement of $0.80 per share, and disclosed a material weakness in internal controls.
Key Events · Legal and Risk Events · HCWB
-
EPS Overstated by $0.80
Q1 2026 basic and diluted EPS was reported at $2.19, but correct figure is $1.39 after properly allocating undistributed earnings to participating warrants.
-
Material Weakness Disclosed
Ineffective technical accounting review over complex warrant instruments led to the error; remediation measures are being implemented.
-
Restatement via 10-Q/A
Company will amend its May 14, 2026 Form 10-Q and update registration statements incorporating the affected financials.
-
Going Concern Context
This restatement follows a going-concern warning in the original 10-Q and a recent reverse stock split to maintain Nasdaq listing.
Analysis · HCWB · Life Sciences
The company's Q1 2026 earnings per share were overstated by $0.80 due to a misapplication of the two-class method for warrants. The restatement cuts reported EPS from $2.19 to $1.39, a 37% reduction. Management also disclosed a material weakness in internal controls over complex warrant instruments, raising concerns about the reliability of financial reporting. This comes amid ongoing going-concern warnings and a recent reverse stock split to maintain Nasdaq listing.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 44.6% of the 296 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCWB was trading at $3.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $1.50 to $44.10. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.